Abstract This article briefly and selectively reviews recent controlled trials of imipramine in agoraphobia. It is concluded that (1) imipramine enhances the effects of exposure treatments of agoraphobia probably due to facilitation of the process of habituation underlying repeated/prolonged exposure to phobic stimuli, (2) that imipramine doses in the range of 150 to 200 mg/d may be required for optimal pharmacological effects and (3) that the extent of imipramine's clinical effects in the absence of exposure and the relationship between its antiphobic, antipanic, and antidepressant actions require further elucidation. Some possibilities for future research are also discussed.